InVivo Therapeutics names new board member
This article was originally published in Scrip
InVivo Therapeutics, a biomaterials and biotechnology company with a focus on treatment of spinal cord injuries, has named Ann Merrifield to its board of directors. Ms Merrifield was most recently president and chief executive officer at PathoGenetix, a genomics company that developed an automated system for rapid bacterial identification from complex samples. She also previously spent 18 years at Genzyme, serving in a number of leadership roles.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.